The New Bio-Economy Gold Rush: Why Data and AI Models are the Ultimate Biotech Assets in 2026

If you are still evaluating biotechnology companies based solely on their physical laboratory space and wet-lab pipelines, you are looking at the past. As of March 22, 2026, the core valuation of the